UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
Dated August 11, 2022
Commission File Number: 001-40286
Arrival
(Translation of registrant’s name into English)
60A, rue des Bruyères
L-1274 Howald,
Grand Duchy of Luxembourg
+352 26845062
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
Exhibit No. | Description | |
99.1 |
Press Release issued by Arrival on August 11, 2022 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.
ARRIVAL | ||
By | /s/ John Wozniak | |
Name: | John Wozniak | |
Title: | Chief Financial Officer |
Dated: August 11, 2022
● |
Arrival Van achieved European Whole Vehicle Type Approval in May
|
● |
Vans are currently being tested on public roads; customer trials scheduled to commence in Central London this quarter with vehicles integrated into customer operations delivering packages through Q4
|
● |
Trials in Europe and North America to commence in 2023
|
● |
Van production in Bicester expected to start this quarter with deliveries to customers expected this year
|
● |
Charlotte Microfactory timeline moved to 2023, capitalizing on learnings and efficiencies from the Bicester Microfactory
|
● |
Achieved European certification in Q2
|
● |
The Arrival Bus has started operating on public roads, taking employees from site to site
|
● |
Customer trials and investment in the Bus microfactory will continue once the Company secures additional capital
|
● |
Loss for the period of $89.6 million, compared to a loss for the period of $56.2 million in the second quarter of 2021
|
● |
Adjusted EBITDA loss for the period of $76.2 million, compared to an adjusted EBITDA loss of $41.2 million in the second quarter of 2021
|
● |
Administrative expenses were $82.2 million and non-capitalized R&D expenses were $32.6 million, compared to administrative expenses of $36.3 million and non-capitalized R&D expenses of $11.6 million in the second quarter of 2021
|
● |
Capital expenditure for the period, including tangible and intangible purchases, of $95.2 million, compared to $79.1 million in the second quarter of 2021
|
● |
Cash and cash equivalents of $512.6 million as of June 30, 2022
|
● |
Established an ATM platform to sell up to $300 million of stock from time to time which provides an additional source of capital needed to deliver business priorities through 2023
|
● |
Shares outstanding totaled 638,237,901 and weighted average shares outstanding in Q2 totaled 633,974,891 as of June 30, 2022
|
● |
Operational assumptions, including, the development and commercialization of Arrival’s vehicles, the roll out of Arrival’s Microfactory manufacturing locations, the production capacity of Arrival’s Microfactories, the selection of
Arrival’s products by customers in the commercial Van and Bus industry, growth in the various markets Arrival is targeting, average selling prices and resulting sales of vehicles.
|
● |
The mix of products produced and sold in combination with corresponding costs, including material and component costs, assembly costs, manufacturing costs, and costs related to product warranties. Many of these costs are forecasted to vary
significantly as Arrival commences production in its Microfactories.
|
● |
Our ability to raise capital necessary to execute on our current business plan and production timeline, including the roll-out of our Microfactories, as well as to maintain our ongoing operations, continue research, development and design
efforts and improve infrastructure.
|
● |
Capital expenditure is based on a number of assumptions regarding the expenditure required to build Arrival’s Microfactories, including the cost of initial set up of factory facilities and the cost of manufacturing and assembly equipment.
|
In thousands of US$
|
6 months to June 30
Q2 2022
|
6 months to June 30
Q2 2021
|
(Loss) for the period
|
(99,950)
|
(1,207,256)
|
Interest expense/(income), net
|
8,609
|
(2,854)
|
Tax expense
|
4,152
|
7,570
|
Depreciation and amortization
|
18,481
|
10,997
|
EBITDA
|
(68,708)
|
(1,191,543)
|
Impairment losses and write-offs(7)
|
47,191
|
2,406
|
Share option expense
|
9,870
|
1,563
|
Listing expense(1)
|
-
|
1,188,335
|
Change in fair value of warrants(2)
|
(3,277)
|
(97,021)
|
Reversal of difference between fair value and nominal value of loans that got repaid(3)
|
(295)
|
(1,742)
|
Fair value movement of embedded derivative(5)
|
(104,931)
|
-
|
Fair value movements on employee loans including changes in estimates re repayment dates(4)
|
3,537
|
-
|
Foreign exchange (gain)/loss, net
|
(26,491)
|
9,630
|
Transaction bonuses(6)
|
-
|
16,062
|
Adjusted EBITDA
|
(143,104)
|
(72,310)
|
(1) |
During the prior period ended June 30, 2021, as a result of the conclusion of the merger with CIIG, Arrival issued shares and warrants to CIIG shareholders, comprised of the fair value of the Company’s shares that were issued to CIIG
shareholders, and in exchange, the Company received the identifiable net assets held by CIIG. The excess of the fair value of the equity instruments issued over the fair value of the identified net assets received, represents a non-cash
expense in accordance with IFRS 2. This one-time expense as a result of the transaction, in the amount of USD $1,888.3 million, is recognised as a share listing expense presented as part of the operating results within the consolidated
statement of profit or loss. Listing expense also includes USD $19.8 million of other related transaction expenses.
|
(2) |
Warrants are fair valued as of the balance sheet date. The change in value is recorded in the consolidated statement of profit or loss.
|
(3) |
Employee loans initially recognised at their fair value are amortized over the period which they are expected to be repaid. Employee loans, which get repaid/settled at an earlier date than what was initially anticipated results in gain in
the consolidated statement of profit or loss.
|
(4) |
The Group has re-financed some loans given to employees in April 2022. As per IFRS 9 the difference between the fair value of the new loans and the carrying amount has been recognised in the consolidated statement of profit or loss.
|
(5) |
An embedded derivative is a component of a hybrid contract that also includes a non-derivative host. The Company has recognised the embedded derivative as part of the convertible notes issued in November 2021 which is fair valued as at
balance sheet date for the six months to June 30,2022. There was no such movement in the prior period of six months to June 30,2021.
|
(6) |
Following the successful merger with CIIG certain executive officers of the Group received a one time bonus. This is included in administrative expenses in the consolidated statement of profit or loss in the prior period of six months to
June 30,2021.
|
(7) |
Impairment losses and write-offs include impairment for lease locations no longer utilized by the Group, impairment on assets as a result of stopping operations in Russia, internally developed intangible assets impaired as a result of
business reorganization and write-offs of aged batteries cells.
|
In thousands of US$
|
3 months to June30
Q2 2022
|
3 months to June 30
Q2 2021
|
(Loss) for the period
|
(89,570)
|
(56,207)
|
Interest expense/(income), net
|
2,056
|
(1,306)
|
Tax expense/(Income)
|
(1,929)
|
7,601
|
Depreciation and amortization
|
9,591
|
5,978
|
EBITDA
|
(79,852)
|
(43,934)
|
Impairment losses and write-offs
|
43,679
|
2,406
|
Share option expense
|
4,740
|
125
|
Change in fair value of warrants(2)
|
(909)
|
(8,445)
|
Reversal of difference between fair value and nominal value of loans that got repaid(3)
|
(295)
|
(10)
|
Fair value movement of embedded derivative(5)
|
(31,731)
|
-
|
Fair value movements on employee loans including changes in estimates re repayment dates(4)
|
3,537
|
-
|
Foreign exchange (gain)/loss, net
|
(15,348)
|
8.675
|
Adjusted EBITDA
|
(76,179)
|
(41,183)
|